Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI – Get Free Report) have received a consensus rating of “Hold” from the twelve research firms that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have assigned a buy rating to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $6.64.
A number of analysts have issued reports on MRVI shares. Craig Hallum cut their target price on Maravai LifeSciences from $12.00 to $10.00 and set a “buy” rating on the stock in a research report on Tuesday, May 13th. Baird R W lowered Maravai LifeSciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 26th. Robert W. Baird cut their price objective on Maravai LifeSciences from $3.00 to $2.00 and set a “neutral” rating on the stock in a research report on Tuesday, May 13th. UBS Group cut their price objective on Maravai LifeSciences from $8.00 to $2.50 and set a “neutral” rating on the stock in a research report on Friday, March 21st. Finally, Morgan Stanley cut their price objective on Maravai LifeSciences from $7.00 to $5.00 and set an “equal weight” rating on the stock in a research report on Tuesday, March 25th.
Check Out Our Latest Analysis on Maravai LifeSciences
Hedge Funds Weigh In On Maravai LifeSciences
Maravai LifeSciences Trading Down 0.9%
MRVI stock opened at $2.26 on Tuesday. The stock has a market cap of $575.53 million, a price-to-earnings ratio of -1.38 and a beta of 0.25. The business’s 50-day moving average is $2.07 and its 200 day moving average is $3.55. Maravai LifeSciences has a 12-month low of $1.67 and a 12-month high of $10.03. The company has a current ratio of 10.74, a quick ratio of 9.94 and a debt-to-equity ratio of 0.89.
Maravai LifeSciences (NASDAQ:MRVI – Get Free Report) last released its quarterly earnings data on Monday, May 12th. The company reported ($0.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.01). Maravai LifeSciences had a negative net margin of 81.13% and a negative return on equity of 6.61%. The business had revenue of $46.85 million during the quarter, compared to analyst estimates of $44.01 million. The company’s revenue was down 26.9% compared to the same quarter last year. On average, sell-side analysts anticipate that Maravai LifeSciences will post -0.24 EPS for the current fiscal year.
About Maravai LifeSciences
Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.
Featured Stories
- Five stocks we like better than Maravai LifeSciences
- What Do S&P 500 Stocks Tell Investors About the Market?
- Ignore the Noise—Samsara Stock Is Still a Strong Buy
- How to Use the MarketBeat Stock Screener
- 3 Stocks Set to Double—And There’s Still Time to Buy
- Expert Stock Trading Psychology Tips
- Analysts Can’t Get Enough of These Little-Known Biopharma Stocks
Receive News & Ratings for Maravai LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maravai LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.